Terms: = Liver cancer AND PTPN11, CFC, Q06124, 5781, ENSG00000179295, SHP2, MGC14433, SHP-2, BPTP3, PTP-1D, SH-PTP3, NS1, SH-PTP2, PTP2C AND Treatment
33 results:
1. Tyrosine phosphatase
Chen X; Keller SJ; Hafner P; Alrawashdeh AY; Avery TY; Norona J; Zhou J; Ruess DA
Front Immunol; 2024; 15():1340726. PubMed ID: 38504984
[TBL] [Abstract] [Full Text] [Related]
2. Increased Siglec-9/Siglec-9L interactions on NK cells predict poor HCC prognosis and present a targetable checkpoint for immunotherapy.
Xiao R; Tian Y; Zhang J; Li N; Qi M; Liu L; Wang J; Li Z; Zhang J; Zhao F; Wang T; Tan S; Li C; Wu Z; Yu M; Jiang X; Zhan P; Gao L; Han B; Liu X; Liang X; Ma C
J Hepatol; 2024 May; 80(5):792-804. PubMed ID: 38331327
[TBL] [Abstract] [Full Text] [Related]
3. ACE2 negatively regulates the Warburg effect and suppresses hepatocellular carcinoma progression via reducing ROS-HIF1α activity.
Dong F; Li H; Liu L; Yao LL; Wang J; Xiang D; Ma J; Zhang G; Zhang S; Li J; Jiang SH; Hu X; Chen J; Bao Z
Int J Biol Sci; 2023; 19(8):2613-2629. PubMed ID: 37215979
[TBL] [Abstract] [Full Text] [Related]
4. Design and Characterization of Mutated Variants of the Oncotoxic Parvoviral Protein ns1.
Hauswirth P; Graber P; Buczak K; Mancuso RV; Schenk SH; Nüesch JPF; Huwyler J
Viruses; 2023 Jan; 15(1):. PubMed ID: 36680249
[TBL] [Abstract] [Full Text] [Related]
5. miR-6071 inhibits hepatocellular carcinoma progression via targeting ptpn11.
Chen M; Wang H; Shi S; Zhang H; Xu S; Jiang Y
Arch Biochem Biophys; 2022 Sep; 727():109345. PubMed ID: 35792156
[TBL] [Abstract] [Full Text] [Related]
6. Pharmaceutical SH2 domain-containing protein tyrosine phosphatase 2 inhibition suppresses primary and metastasized liver tumors by provoking hepatic innate immunity.
Liu JJ; Xin B; Du L; Chen L; Long Y; Feng GS
Hepatology; 2023 May; 77(5):1512-1526. PubMed ID: 35503714
[TBL] [Abstract] [Full Text] [Related]
7. Inhibition of BTK and PI3Kδ impairs the development of human JMML stem and progenitor cells.
Ramdas B; Yuen LD; Palam LR; Patel R; Pasupuleti SK; Jideonwo V; Zhang J; Maguire C; Wong E; Kanumuri R; Zhang C; Sandusky G; Chan RJ; Zhang C; Stieglitz E; Haneline L; Kapur R
Mol Ther; 2022 Jul; 30(7):2505-2521. PubMed ID: 35443935
[TBL] [Abstract] [Full Text] [Related]
8. Overriding Adaptive Resistance to Sorafenib Through Combination Therapy With Src Homology 2 Domain-Containing Phosphatase 2 Blockade in Hepatocellular Carcinoma.
Leung CON; Tong M; Chung KPS; Zhou L; Che N; Tang KH; Ding J; Lau EYT; Ng IOL; Ma S; Lee TKW
Hepatology; 2020 Jul; 72(1):155-168. PubMed ID: 31610028
[TBL] [Abstract] [Full Text] [Related]
9. Is Resection of Primary Midgut Neuroendocrine Tumors in Patients with Unresectable Metastatic liver Disease Justified? A Systematic Review and Meta-Analysis.
Tsilimigras DI; Ntanasis-Stathopoulos I; Kostakis ID; Moris D; Schizas D; Cloyd JM; Pawlik TM
J Gastrointest Surg; 2019 May; 23(5):1044-1054. PubMed ID: 30671800
[TBL] [Abstract] [Full Text] [Related]
10. miR-500a-3p promotes cancer stem cells properties via STAT3 pathway in human hepatocellular carcinoma.
Jiang C; Long J; Liu B; Xu M; Wang W; Xie X; Wang X; Kuang M
J Exp Clin Cancer Res; 2017 Jul; 36(1):99. PubMed ID: 28750679
[TBL] [Abstract] [Full Text] [Related]
11. A pumpkin polysaccharide induces apoptosis by inhibiting the JAK2/STAT3 pathway in human hepatoma HepG2 cells.
Shen W; Chen C; Guan Y; Song X; Jin Y; Wang J; Hu Y; Xin T; Jiang Q; Zhong L
Int J Biol Macromol; 2017 Nov; 104(Pt A):681-686. PubMed ID: 28634059
[TBL] [Abstract] [Full Text] [Related]
12. shp2 is induced by the HBx-NF-κB pathway and contributes to fibrosis during human early hepatocellular carcinoma development.
Kang HJ; Chung DH; Sung CO; Yoo SH; Yu E; Kim N; Lee SH; Song JY; Kim CJ; Choi J
Oncotarget; 2017 Apr; 8(16):27263-27276. PubMed ID: 28460481
[TBL] [Abstract] [Full Text] [Related]
13. shp2 promotes liver cancer stem cell expansion by augmenting β-catenin signaling and predicts chemotherapeutic response of patients.
Xiang D; Cheng Z; Liu H; Wang X; Han T; Sun W; Li X; Yang W; Chen C; Xia M; Liu N; Yin S; Jin G; Lee T; Dong L; Hu H; Wang H; Ding J
Hepatology; 2017 May; 65(5):1566-1580. PubMed ID: 28059452
[TBL] [Abstract] [Full Text] [Related]
14. Cooperation of MLL/AF10(OM-LZ) with ptpn11 activating mutation induced monocytic leukemia with a shorter latency in a mouse bone marrow transplantation model.
Fu JF; Liang ST; Huang YJ; Liang KH; Yen TH; Liang DC; Shih LY
Int J Cancer; 2017 Mar; 140(5):1159-1172. PubMed ID: 27859216
[TBL] [Abstract] [Full Text] [Related]
15. Functions of shp2 in cancer.
Zhang J; Zhang F; Niu R
J Cell Mol Med; 2015 Sep; 19(9):2075-83. PubMed ID: 26088100
[TBL] [Abstract] [Full Text] [Related]
16. ptpn11/shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients.
Han T; Xiang DM; Sun W; Liu N; Sun HL; Wen W; Shen WF; Wang RY; Chen C; Wang X; Cheng Z; Li HY; Wu MC; Cong WM; Feng GS; Ding J; Wang HY
J Hepatol; 2015 Sep; 63(3):651-60. PubMed ID: 25865556
[TBL] [Abstract] [Full Text] [Related]
17. Negative regulation of signal transducer and activator of transcription-3 signalling cascade by lupeol inhibits growth and induces apoptosis in hepatocellular carcinoma cells.
Siveen KS; Nguyen AH; Lee JH; Li F; Singh SS; Kumar AP; Low G; Jha S; Tergaonkar V; Ahn KS; Sethi G
Br J Cancer; 2014 Sep; 111(7):1327-37. PubMed ID: 25101566
[TBL] [Abstract] [Full Text] [Related]
18. New BRAF knockin mice provide a pathogenetic mechanism of developmental defects and a therapeutic approach in cardio-facio-cutaneous syndrome.
Inoue S; Moriya M; Watanabe Y; Miyagawa-Tomita S; Niihori T; Oba D; Ono M; Kure S; Ogura T; Matsubara Y; Aoki Y
Hum Mol Genet; 2014 Dec; 23(24):6553-66. PubMed ID: 25035421
[TBL] [Abstract] [Full Text] [Related]
19. Oncogenic KIT-induced aggressive systemic mastocytosis requires shp2/ptpn11 phosphatase for disease progression in mice.
Sharma N; Everingham S; Zeng LF; Zhang ZY; Kapur R; Craig AW
Oncotarget; 2014 Aug; 5(15):6130-41. PubMed ID: 25026279
[TBL] [Abstract] [Full Text] [Related]
20. Embelin reduces colitis-associated tumorigenesis through limiting IL-6/STAT3 signaling.
Dai Y; Jiao H; Teng G; Wang W; Zhang R; Wang Y; Hebbard L; George J; Qiao L
Mol Cancer Ther; 2014 May; 13(5):1206-16. PubMed ID: 24651526
[TBL] [Abstract] [Full Text] [Related]
[Next]
